EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study

Edward J D Webb iD, Daniel Howdon, Rebecca Bestwick, Natalie King, Jonathan A T Sandoe iD, Joanne Euden iD, Detelina Grozeva iD, Robert West, Philip Howard iD, Neil Powell iD, Mahableshwar Albur, Stuart Bond iD und 16 weitere

Journal of Antimicrobial Chemotherapy · 2024

DOI: 10.1093/jac/dkae167 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, 2024. Verfasst von Edward J D Webb und 27 weiteren Autor:innen. Beteiligte Einrichtung: Leeds Institute for Health Sciences, University of Leeds, Leeds, UK. Hauptthemen laut MEDLINE: Procalcitonin, Cost-Benefit Analysis, Anti-Bacterial Agents, COVID-19. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute for Health, HCRW_, Health and Care Research Wales.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Many hospitals introduced procalcitonin (PCT) testing to help diagnose bacterial coinfection in individuals with COVID-19, and guide antibiotic decision-making during the COVID-19 pandemic in the UK.

Objectives

Evaluating cost-effectiveness of using PCT to guide antibiotic decisions in individuals hospitalized with COVID-19, as part of a wider research programme.

Methods

Retrospective individual-level data on patients hospitalized with COVID-19 were collected from 11 NHS acute hospital Trusts and Health Boards from England and Wales, which varied in their use of baseline PCT testing during the first COVID-19 pandemic wave. A matched analysis (part of a wider analysis reported elsewhere) created groups of patients whose PCT was/was not tested at baseline. A model was created with combined decision tree/Markov phases, parameterized with quality-of-life/unit cost estimates from the literature, and used to estimate costs and quality-adjusted life years (QALYs). Cost-effectiveness was judged at a £20 000/QALY threshold. Uncertainty was characterized using bootstrapping.

Results

People who had baseline PCT testing had shorter general ward/ICU stays and spent less time on antibiotics, though with overlap between the groups’ 95% CIs. Those with baseline PCT testing accrued more QALYs (8.76 versus 8.62) and lower costs (£9830 versus £10 700). The point estimate was baseline PCT testing being dominant over no baseline testing, though with uncertainty: the probability of cost-effectiveness was 0.579 with a 1 year horizon and 0.872 with a lifetime horizon.

Conclusions

Using PCT to guide antibiotic therapy in individuals hospitalized with COVID-19 is more likely to be cost-effective than not, albeit with uncertainty.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProcalcitoninCost-Benefit AnalysisAnti-Bacterial AgentsCOVID-19HumansMaleRetrospective StudiesFemaleMiddle AgedAgedHospitalizationSARS-CoV-2Quality-Adjusted Life YearsAdultCOVID-19 Drug TreatmentUnited KingdomBacterial Infections

Substanzen

ProcalcitoninAnti-Bacterial Agents

Autor:innen und Institutionen

  • Leeds Institute for Health Sciences, University of Leeds, Leeds, UK.
  • Healthcare Associated Infection Group, Leeds Institute of Medical Research, University of Leeds, Leeds, UK.
  • Department of Microbiology, Leeds Teaching Hospitals NHS Trust, Leeds, UK.
  • Centre for Trials Research, College of Biomedical and Life Sciences, Cardiff University, Cardiff, UK.
  • NHS England North-East & Yorkshire, Leeds, UK.
  • Pharmacy Department, Royal Cornwall Hospital, Royal Cornwall Hospitals NHS Foundation Trust, Truro TR1 3LJ, UK.

ORCID-Profile: Edward J D Webb, Jonathan A T Sandoe, Joanne Euden, Detelina Grozeva, Philip Howard, Neil Powell, Stuart Bond, Paul Dark, David Partridge

Förderung

  • National Institute for Health
  • HCRW_
  • Health and Care Research Wales

Zitieren

APA

Webb, E. J. D., Howdon, D., Bestwick, R., King, N., Sandoe, J. A. T., Euden, J., Grozeva, D., West, R., Howard, P., Powell, N., Albur, M., Bond, S., Brookes-Howell, L., Dark, P., Hellyer, T., Llewelyn, M., McCullagh, I. J., Ogden, M., Pallmann, P., …, & PEACH Study Group (2024). The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study. Journal of Antimicrobial Chemotherapy. https://doi.org/10.1093/jac/dkae167

Vancouver

Webb EJD, Howdon D, Bestwick R, King N, Sandoe JAT, Euden J, et al. The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study. Journal of Antimicrobial Chemotherapy. 2024. doi:10.1093/jac/dkae167

BibTeX
@article{Webb2024,
  author = {Webb, Edward J D and Howdon, Daniel and Bestwick, Rebecca and King, Natalie and Sandoe, Jonathan A T and Euden, Joanne and Grozeva, Detelina and West, Robert and Howard, Philip and Powell, Neil and Albur, Mahableshwar and Bond, Stuart and Brookes-Howell, Lucy and Dark, Paul and Hellyer, Thomas and Llewelyn, Martin and McCullagh, Iain J and Ogden, Margaret and Pallmann, Philip and Parsons, Helena and Partridge, David and Shaw, Dominick and Szakmany, Tamas and Todd, Stacy and Thomas-Jones, Emma and Carrol, Enitan D and Shinkins, Bethany and PEACH Study Group, PEACH Study Group},
  title = {The cost-effectiveness of procalcitonin for guiding antibiotic prescribing in individuals hospitalized with COVID-19: part of the PEACH study},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2024},
  doi = {10.1093/jac/dkae167}
}
Infokarte | EUVIMED

Artikeldaten derzeit nicht verfügbar.

Recherche